The Effects of Cyclosporine and Aspirin on Platelet Function in Normal Dogs

J. Thomason, T. Archer, R. Wills, S. Press, and A. Mackin

Background: Cyclosporine increases thromboxane synthesis in dogs, potentially increasing the thrombogenic properties of platelets.

Hypothesis/Objectives: Our hypothesis was that the concurrent administration of low-dose aspirin and cyclosporine would inhibit cyclosporine-associated thromboxane synthesis without altering the antiplatelet effects of aspirin. The objective was to determine the effects of cyclosporine and aspirin on primary hemostasis.

Animals: Seven healthy dogs.

Methods: A randomized, crossover study utilized turbidimetric aggregometry and a platelet function analyzer to evaluate platelet function during the administration of low-dose aspirin (1 mg/kg PO q24h), high-dose aspirin (10 mg/kg PO q12h), cyclosporine (10 mg/kg PO q12h), and combined low-dose aspirin and cyclosporine. The urine 11-dehydro-thromboxane-B2 (11-dTXB2)-to-creatinine ratio also was determined.

Results: On days 3 and 7 of administration, there was no difference in the aggregometry amplitude or the platelet function analyzer closure time between the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group. On day 7, there was a significant difference in amplitude and closure time between the cyclosporine group and the combined low-dose aspirin and cyclosporine group. High-dose aspirin consistently inhibited platelet function. On both days, there was a significant difference in the urinary 11-dTXB2-to-creatinine ratio between the cyclosporine group and the combined low-dose aspirin and cyclosporine groups. High-dose aspirin always inhibited platelet function.

Conclusions and Clinical Importance: Low-dose aspirin inhibits cyclosporine-induced thromboxane synthesis, and concurrent use of these medications does not alter the antiplatelet effects of aspirin.

Key words: Canine; Immune-mediated hemolytic anemia; Immunosuppression; Thromboxane.

Immune-mediated hemolytic anemia (IMHA) is a common cause of anemia in dogs.1 Unfortunately, despite treatment efforts, mortality rates for IMHA in dogs are 50–70%.2 One of the most common causes of death in dogs with IMHA is thromboembolic disease, particularly pulmonary thromboembolism (PTE). The incidence of PTE in dogs with IMHA may be as high as 50–80%.3 The exact mechanisms leading to thrombus formation and PTE in dogs with IMHA are complicated, but one contributing factor is thought to be disruptions in normal platelet function.4,5 Dogs with IMHA have been shown to have hyperactive platelets associated with platelet plasma membrane alterations.4 Activated platelets release vasoactive molecules such as serotonin and thromboxane A2, which may contribute to a hypercoagulable state and predisposition to PTE.5

Treatment of IMHA in dogs typically consists of immunosuppressive medications, drugs that inhibit hemostasis, and supportive care. Although glucocorticoids are the cornerstone of immunosuppressive therapy, additional immunosuppressive agents often are needed, and these drugs commonly are associated with adverse effects that can be deleterious to the patient, undesirable to owners or both. Cyclosporine has become a popular drug for the treatment of IMHA in dogs because of perceived safety and minimal adverse effects associated with its use.6

In humans, cyclosporine increases platelet synthesis of thromboxane A2.7,8 Thromboxane A2 triggers vasoconstriction, causes platelet activation, and enhances platelet aggregation, all of which will decrease blood flow, increase blood stasis, and promote coagulation.9 When compared to renal transplant recipients treated with azathioprine, human patients receiving cyclosporine have increased thromboxane A2 production and

Abbreviations:

- 11-dTXB2: 11-dehydro-thromboxane-B2
- ADP: adenosine diphosphate
- COX: cyclooxygenase
- IMHA: immune-mediated hemolytic anemia
- PFA: platelet function analyzer
- PPP: platelet-poor plasma
- PRP: platelet-rich plasma
- PTE: pulmonary thromboembolism

From the Departments of Clinical Sciences (Thomason, Archer, Press, Mackin); and Pathobiology and Population Medicine (Wills), College of Veterinary Medicine, Mississippi State University, MS 39762-6100.

This work was performed at the College of Veterinary Medicine, Mississippi State University.

Abstract previously presented in part at the 2014 ACVIM Forum, Nashville, TN, June 2014.

The authors thank Matthew Raby, Cyndi Dunaway, Claire Fellman, and Jenica Haraschak for their assistance.

Corresponding author: J. Thomason, Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, PO Box 6100, MS 39762-6100; e-mail: thomason@cvm.msstate.edu

Submitted December 17, 2015; Revised March 22, 2016; Accepted April 14, 2016.

Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1111/jvim.13960
increased rates of thrombus formation within the renal parenchyma. In dogs, similar to humans, the administration of cyclosporine is associated with a significant increase in thromboxane synthesis, especially at immunosuppressive cyclosporine dosages and at times of peak blood drug concentrations. This increase in thromboxane synthesis suggests that standard immunosuppressive dosages of cyclosporine might enhance platelet activation in dogs, potentially predisposing hypercoagulable patients to thromboembolic complications.

Drugs that inhibit hemostasis routinely are used prophylactically in dogs with IMHA in an attempt to prevent thromboembolism. Many of these drugs can only be given by injection, are cost prohibitive or both, leaving PO low-dose aspirin as one of the most affordable options for prophylactic therapy. In fact, the use of low-dose aspirin has been shown to improve survival rates in dogs diagnosed with IMHA. Aspirin is a cyclooxygenase (COX) inhibitor that irreversibly inhibits platelet function. The COX enzyme is essential for the conversion of arachidonic acid to several biologically active prostaglandins, including thromboxane A2, that are necessary for normal hemostasis. By inhibiting COX, aspirin decreases platelet synthesis of thromboxane A2, thereby inhibiting platelet function.

Cyclosporine and low-dose aspirin often are used concurrently in dogs with IMHA. Currently, however, it is unknown if low-dose aspirin counteracts cyclosporine-associated thromboxane synthesis and, alternatively, if cyclosporine counteracts the antiplatelet effects of aspirin. Our study was designed to evaluate the effects of cyclosporine and aspirin (both low-dose and high-dose) given as a sole drug, and of concurrent administration of PO cyclosporine and low-dose aspirin, on platelet function and thromboxane synthesis in normal dogs.

Materials and Methods

Study Design, Animals

Eight healthy intact Walker hound dogs, 7 females and 1 male, were used in this study. The dogs had not received any medications or vaccines for at least 1 month before initiation of the study. Normal health status was established by detection of no abnormalities on physical examination, CBC (including manual platelet count), serum biochemistry, urinalysis, and heartworm testing. However, during the early phases of the study, 1 female dog was diagnosed with hepatic lymphoma and removed from the study, and results from this dog were excluded from analysis. The median age of the remaining 7 dogs was 3.5 years (range, 2.5–10.5 years), and their median body weight was 25.8 kg (range, 19.4–31.4 kg). Body weight was obtained at the beginning of the study and used to calculate all subsequent drug doses. Animal use was approved by the Mississippi State University Institutional Animal Care and Use Committee and was in compliance with the requirements of a facility accredited by the American Association for Accreditation of Laboratory Animal Care.

In a 4-way, randomized, crossover study, the dogs were given either low-dose aspirin (1.0 ± 0.03 mg/kg [mean ± SD] PO q24h), high-dose aspirin (9.9 ± 0.3 mg/kg PO q12h), cyclosporine (9.9 ± 0.4 mg/kg PO q12h), or combined low-dose aspirin and cyclosporine (1.0 ± 0.03 mg/kg PO q24h and 9.9 ± 0.4 mg/kg PO q12h, respectively). All drugs were administered PO for 7 days, followed by at least a 14 day washout period before dosing. In our previous low-dose aspirin and cyclosporine studies, platelet function had returned to baseline values within 2 weeks of discontinuing the medications. After the 14-day washout period, the dogs switched groups, and the study was continued until all dogs had received each medication dose and combination.

Samples were collected for platelet function testing and urinary thromboxane analysis. For all medication groups, blood and urine samples were collected on day 0 (before drug administration) and again on days 3 and 7 of drug administration. For all medication groups, samples were collected at the time of estimated peak cyclosporine blood concentrations, which previously has been shown to be 2 hours after drug administration. Blood samples were collected by jugular venipuncture with a 20-gauge needle directly into a 4.5-mL vacutainer tube containing 3.2% sodium citrate anticoagulant. Each sample was collected with a ratio of 1:9 of citrate to blood to standardize the degree of anticoagulation. For urine samples, an ultrasound-guided cystocentesis using a 22-gauge 1.5 inch needle with a 6 mL syringe was performed. The volume of urine collected varied between 2 and 5 mL.

Platelet Function Analyzer

Turbidimetric Platelet Aggregometry. A 2-channel platelet aggregometer that allowed for 2 samples to be evaluated concurrently was used to analyze platelet aggregation in platelet-rich plasma (PRP). On each day of collection, samples were analyzed in duplicate, twice, for a total of 4 results, which were averaged to yield a single value at each time point. Aggregation was assessed using collagen as an agonist (final concentration, 10 µg/mL), a temperature of 37°C, and a stirring speed of 1,200 rpm. All samples were analyzed within 4 hours of collection.

To harvest PRP, whole blood collected into 3.2% sodium citrate was centrifuged at 1,200 rpm at room temperature for 3 minutes. Supernatant PRP was collected, and the remaining blood sample was centrifuged at 1,800 rpm at room temperature for 8 minutes to create platelet-poor plasma (PPP). Samples were analyzed based on the manufacturer’s standard guidelines. Briefly, 450 µL of PRP was transferred into a glass cuvette containing a siliconized magnetic stir bar, and 500 µL of PPP was placed into a cuvette without a stir bar. Samples were incubated at 37°C, for 5 minutes, and placed into the aggregometer, and stable baseline values for minimal (PRP) and maximal (PPP) aggregation were obtained (assigned values of 0 and 100% aggregation, respectively). Collagen was added to the PRP, and aggregation was monitored for 12 minutes. The percentage aggregation at maximum amplitude was calculated and recorded using computer software. The number of platelets within the PRP was not adjusted to a standardized count by dilution with PPP before analysis, based on recommendations published by the International Society of Thrombosis and Haemostasis Platelet Physiology and Scientific and Standardization Committee. Before initiation of the study, all dogs were confirmed to have hematocrit and platelet counts within reference ranges.

Platelet Function Analyzer

A point-of-care platelet function analyzer (PFA-100) that has been evaluated previously for use in dogs was used to analyze platelet function. The PFA-100 assesses platelet function under high shear forces and after activation with several platelet agonists to measure the closure time, in seconds, needed to form a platelet plug and inhibit blood flow. The cutoff time for the instrument is >300 seconds.
The instrument was used according to the manufacturer’s instructions. Briefly, blood samples were collected directly into blood collection tubes containing 3.2% sodium citrate and kept at room temperature without agitation until analysis. For analysis, 800 μl of whole blood was transferred into PFA-100 cartridges (collagen/ADP or collagen/epinephrine),25,26 and analyzed. The collagen/ADP cartridge was utilized initially to establish normal platelet function, and the collagen/epinephrine cartridge then was used throughout the study to assess drug-associated platelet dysfunctions. Two collagen/epinephrine cartridges were analyzed at each time point for all dogs, and the closure times were averaged. All samples were analyzed within 2 hours of collection.

**Urinary Thromboxane**

Urinary 11-dehydro-thromboxane B₂ (11-dTXB₂) concentration was analyzed using an enzyme-linked immunosorbent assay kit27 that has been validated previously in dogs.24 Urine samples were collected by cystocentesis and stored at −80°C for later analysis. Before analysis, samples were thawed to room temperature and diluted with the assay buffer. A correction factor was applied to account for the dilution. Samples were analyzed in triplicate according to the manufacturer’s instructions and reported in picograms per milliliter of urine. Briefly, a 96-well plate was prepared by adding the dilute sample, 11-dTXB₂ monoclonal acetylcholinesterase tracer and 11-dTXB₂ monoclonal antibody to each well, and then incubated at room temperature, in the dark and on an orbital shaker. Ellman’s reagent was added to each well, and the plate was incubated again at room temperature, in the dark and on an orbital shaker. The plate was analyzed at a wavelength of 412 nm using a plate reader.6 Urine creatinine concentration was measured using a biochemistry analyzer28 and used to calculate a urinary 11-TXB₂-to-creatinine ratio.

**Low-Dose Aspirin Response**

Based on previously published criteria used for dogs,29 for both the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group, each dog was, on both days, classified as either an aspirin responder or an aspirin nonresponder. For turbidimetric aggregometry, a dog was considered to be an aspirin responder if there was a >25% decrease in the percentage aggregation at maximum amplitude compared to day 0 values. For the PFA-100, a dog was considered to be an aspirin responder if the closure time was >300 seconds.

**Statistical Analysis**

Histograms were used to visually assess if the measured outcomes were normally distributed using a statistical computer program.30 The distributions of the outcome measures were not consistently normally distributed. Accordingly, additional diagnostic procedures were conducted to ensure that the proper statistical methods were utilized. To determine the effect of day on each outcome measured within a treatment group, a mixed model analysis was conducted. For each marker of platelet function measured within a treatment group, a model was fit with fixed effects of day, period, and day-by-period interaction. Dog was included as a random effect. The repeated measures of dog within period were accounted for in a repeated statement. The distribution of the conditional residuals was evaluated for each marker to ensure the assumptions of the statistical method had been met. Mixed models also were fit that included day, period, group, day-by-period interaction, day-by-group interaction, and group-by-period interaction terms as fixed effects. Differences in least squares means with Tukey adjustment for multiple comparisons were determined for markers with significant main effect or interaction terms. An alpha level of 0.05 was used to determine statistical significance for all methods.

**Results**

**Turbidimetric Aggregometry**

The median turbidimetric aggregometry maximum amplitude for the low-dose aspirin group on day 0 was 48.3% (range, 35.3–63.5%), whereas the maximum amplitude on day 3 and day 7 was 38% (range, 25.3–58.3%) and 10.3% (range, 1.6–76.8%), respectively. When compared to day 0, there was a significant decrease in amplitude on day 7 (P < 0.0261). There was no significant difference in amplitude between days 0 and 3 and days 3 and 7 (Fig 1A). The median maximum amplitude for the high-dose aspirin group on day 0 was 53.3% (range, 46–75.3%), whereas the median amplitude on day 3 and day 7 was 1.8% (range, 0.3–2.3%) and 1.5% (range, 0.5–2.3%), respectively. When compared to day 0, there was a significant decrease in amplitude on both day 3 (P < 0.0001) and day 7 (P < 0.0001). There was no significant difference in amplitude between days 3 and 7 (Fig 1B).

The median maximum amplitude for the cyclosporine group on day 0 was 63.5% (range, 46–76.5%), whereas the median amplitude on day 3 and day 7 was 58.3% (range, 21.3–68%) and 56% (range, 47.5–75.5%), respectively. There was a significant decrease in amplitude among days 0, 3, and 7 (Fig 1C). The median maximum amplitude for the combined low-aspirin and cyclosporine group on day 0 was 51.8% (range, 39.8–75%), whereas the median amplitude on day 3 and day 7 was 38.5% (range, 1.3–63.8%) and 3% (range, 1.5–5.5%), respectively. When compared to day 0, there was a significant decrease in amplitude on day 7 (P < 0.0243). There was no significant difference in amplitude between days 0 and 3 and days 3 and 7 (Fig 1D).

There was no difference in the median maximum amplitude on day 0 for any of the 4 medication groups. However, on day 3, when compared to the 3 other medication groups, there was a significant decrease in amplitude in the high-dose aspirin group (P < 0.0001). There was no difference in amplitude among the cyclosporine group, the low-dose aspirin group, and the combined low-dose aspirin and cyclosporine group. On day 7, there was a significant difference between the low-dose and high-dose aspirin groups (P = 0.012) and between the high-dose aspirin and cyclosporine groups (P < 0.0001). Additionally, on day 7, there was a significant (P < 0.0001) difference between amplitudes in the cyclosporine group and the combined low-dose aspirin and cyclosporine group. However, there was no difference between the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group.

For the low-dose aspirin group, 3 dogs were considered to be aspirin responders on day 3, whereas 5 dogs were aspirin responders on day 7. All 3 dogs that were considered aspirin responders on day 3 also were
classified as aspirin responders on day 7. For the combined low-dose aspirin and cyclosporine group, 4 dogs were aspirin responders on day 3, and 5 dogs were aspirin responders on day 7. The 4 dogs classified as aspirin responders on day 3 also were considered aspirin responders on day 7. On day 3, the 3 dogs that were classified as aspirin responders in the low-dose aspirin group also were considered aspirin responders in the combined low-dose aspirin and cyclosporine group. Similarly, on day 7, the 4 dogs that were classified as aspirin responders in the low-dose aspirin group also were considered aspirin responders in the combined low-dose aspirin and cyclosporine group.

Platelet Function Analysis

The median PFA-100 closure time using the collagen/ADP cartridge was 65 seconds (range, 52–83 seconds). The median PFA-100 closure time using the collagen/epinephrine cartridge for the low-dose aspirin group on day 0 was 112.5 seconds (range, 66–243 seconds), whereas the median closure time on day 3 and day 7 was 132.5 seconds (range, 86–254.5 seconds) and 243.5 seconds (range, 89–300 seconds), respectively. When compared to day 0, there was a significant increase in closure time on day 7 ($P = .0428$). There was no significant difference in closure times between days 0 and 3 and days 3 and 7 (Fig 2A). The median closure time for the high-dose aspirin group on day 0 was 110 seconds (range, 75–155 seconds), whereas the median closure time on day 3 and day 7 was 300 seconds (range, 237–300 seconds) and 300 seconds (range, 186–300), respectively. When compared to day 0, there was a significant increase in closure time on both day 3 ($P = .0003$) and day 7 ($P = .0003$). There was no significant difference in closure time between days 3 and 7 (Fig 2B).

The median closure time using the collagen/epinephrine cartridge for the cyclosporine group on day 0 was 130.5 seconds (range, 98–195 seconds), whereas the median closure time on day 3 and day 7 was 117 seconds (range, 91.5–191 seconds) and 126.5 seconds (range, 92.5–138 seconds), respectively. There was no significant difference in closure times among days 0, 3, and 7 (Fig 2C). The median closure time for the combined low-dose aspirin and cyclosporine group on day 0
was 103 seconds (range, 78–172 seconds), whereas the median closure time on day 3 and day 7 was 134.5 seconds (range, 94.5–161.5 seconds) and 266 seconds (range, 150.5–300 seconds), respectively. When compared to day 0, there was no difference in closure time on day 3, but there was a significant increase in closure time on day 7 \((P = .0012)\). There was a significant difference \((P = .0021)\) in closure time between days 3 and 7. (Fig 2D).

There was no difference in the median closure time on day 0 for any of the 4 medication groups. On day 3, when compared to the 3 other medication groups, there was a significant increase in the median closure time in the high-dose aspirin group. There was no difference in the closure time among the cyclosporine group, the low-dose aspirin group, and the combined low-dose aspirin and cyclosporine group. On day 7, there was a significant difference in closure time between the low-dose and high-dose aspirin groups \((P = .0043)\) and between the low-dose aspirin and cyclosporine groups \((P < .0001)\). Additionally, there was a significant \((P < .0001)\) difference between the closure time in the cyclosporine group and the combined low-dose aspirin and cyclosporine group. However, there was no difference between the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group.

On day 3, all dogs in both the low-dose aspirin and the combined low-dose aspirin and cyclosporine groups were considered to be aspirin nonresponders. On day 7, 3 dogs were considered to be aspirin responders in the low-dose aspirin group and 2 dogs were considered to be aspirin responders in the combined low-dose aspirin and cyclosporine group. However, only 1 dog on day 7 was considered to be a responder in both the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group.

**Urinary Thromboxane**

The median 11-dTXB\(_2\)-to-creatinine ratio for the low-dose aspirin group on day 0 was 6.3 (range, 2.6–32.2), whereas the median ratio on day 3 and day 7 was 3.0 (range, 1–6.6) and 3.2 (range, 1–4.5), respectively (Fig 3A). The median 11-dTXB\(_2\)-to-creatinine ratio for the high-dose aspirin group on day 0 was 4.5 (range, 1.8–13.1), whereas the median ratio on day 3 and day 7

---

**Fig 2.** PFA-100\textsuperscript{\circledR} closure times (collagen/epinephrine cartridge) in dogs treated with (A) low-dose aspirin, (B) high-dose aspirin, (C) cyclosporine, and (D) low-dose aspirin and cyclosporine. The box and whiskers plot demonstrates the median (line), interquartile range (box), and total range (whiskers).
was 2.7 (range, 1.4–6.9) and 3.0 (range, 0.6–17.9), respectively (Fig 3B). For both the low-dose aspirin group and the high-dose aspirin group, there were no significant differences in 11-dTXB₂-to-creatinine ratio among days 0, 3, and 7.

The median 11-dTXB₂-to-creatinine ratio for the cyclosporine group on day 0 was 4.2 (range, 3.3–18.1), whereas the median ratio on day 3 and day 7 was 8.6 (range, 3.8–37.9) and 7.6 (range, 4.9–73.5), respectively. When compared to day 0, there was a significant increase in the median 11-dTXB₂-to-creatinine ratio on day 3 \((P = .0064)\) and on day 7 \((P < .0001)\). There was also a significant difference in the 11-dTXB₂-to-creatinine ratio between days 3 and 7 \((P = .0003)\); (Fig 3C). The median 11-dTXB₂-to-creatinine ratio for the combined low-dose aspirin and cyclosporine group on day 0 was 5.2 (range, 3.1–11.5), whereas the median ratio on day 3 and day 7 was 6.5 (range, 3.2–10.6) and 3.9 (range, 1.6–7.2), respectively. There were no significant differences in the 11-dTXB₂-to-creatinine ratio among days 0, 3, and 7 (Fig 3D).

There was no difference in the median 11-dTXB₂-to-creatinine ratio on day 0 for any of the 4 medication groups. There was a significant difference between the cyclosporine group and the combined low-dose aspirin and cyclosporine group on day 3 \((P = .0268)\) and day 7 \((P < .0001)\). On both days, there was no difference among the high-dose aspirin group, the low-dose aspirin group, and the combined low-dose aspirin and cyclosporine group.

**Discussion**

Cyclosporine is a commonly used immunosuppressive agent in dogs, partly because of the perception of relatively minimal adverse effects. However, several studies in humans have indicated that cyclosporine can increase the risk of thromboembolic complications by increasing synthesis of thromboxane A₂. Recently, similar to humans, it has been shown that cyclosporine, especially at the time of peak blood drug concentrations, increases synthesis of thromboxane in...
dogs in a dose-dependent manner. The results of our current study confirm that, when cyclosporine is administered to dogs at an immunosuppressive dosage, there is a significant increase in thromboxane synthesis. The exact mechanism for the increase in thromboxane is unknown.

Once synthesized, thromboxane A₂ triggers vasoconstriction, causes platelet activation, and enhances platelet aggregation, all of which will increase blood stasis and contribute to thrombogenesis. After synthesis, thromboxane A₂ is converted rapidly to several metabolites that then are eliminated in the urine. Measurement of urine concentrations of a stable thromboxane metabolite such as 11-dTXB₂ is considered a reliable marker of systemic thromboxane A₂ production. Although platelets generate substantial amounts of thromboxane A₂, other cells, such as leukocytes and endothelial cells, are capable of synthesizing this eicosanoid. Some of the urinary 11-dTXB₂ measured in our study therefore may have been derived these additional cells and not solely platelets. Regardless of the source of thromboxane, it is well established that cyclosporine administration in dogs is associated with increased thromboxane synthesis. Increased thromboxane synthesis would be expected to enhance platelet reactivity in some dogs. Only about 30% of dogs, however, have platelets that are sensitive to the effects of thromboxane, suggesting that drug-induced increases in thromboxane synthesis may not reliably increase platelet reactivity in all dogs. Even if platelets do not consistently respond to thromboxane stimulation in dogs, thromboxane still may contribute to vasoconstriction, which may in turn increase the risk of thrombus formation.

Because IMHA in dogs enhances the risk of thromboembolism, a thrombotic increase in thromboxane synthesis could predispose these patients to excessive thrombus formation. Antiplatelet therapy such as low-dose aspirin is commonly administered to IMHA patients to inhibit platelet function in an effort to prevent thromboembolism. Aspirin irreversibly inhibits platelet function by preventing the synthesis of thromboxane. Low-dose aspirin (1 mg/kg PO q24h) in dogs significantly decreased urinary 11-dTXB₂-to-creatinine ratios within 3 days of starting therapy. In our study, we also identified a numerical decrease in the 11-dTXB₂-to-creatinine ratio after administration of low-dose aspirin, but the decrease was not significant between day 0 and days 3 or 7. One likely explanation for the discrepancy between these 2 studies is that our study enrolled a smaller number of dogs compared to the previous study and therefore may have lacked sufficient power to detect a difference between pre- and post-treatment results. Measurement of urinary 2,3-dinor thromboxane B₂, a thromboxane metabolite that is more sensitive to the effects of aspirin in dogs than is 11-dTXB₂, may have permitted the detection of more subtle decreases in thromboxane synthesis, but unfortunately this assay was not available at the time of our study.

In our study, there was no difference between the 11-dTXB₂-to-creatinine ratio results in the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group. Additionally, when compared to the administration of cyclosporine alone, the concurrent use of cyclosporine with low-dose aspirin caused a significant decrease in the 11-dTXB₂-to-creatinine ratio, suggesting that low-dose aspirin will prevent cyclosporine-induced thromboxane synthesis. The results of our study suggest that when these 2 drugs are used concurrently, the pharmacological effects of low-dose aspirin overcome cyclosporine-induced thromboxane synthesis and potentially decrease the risk of thromboembolism created by cyclosporine therapy. A similar phenomenon has been observed in rats that were exposed to both drugs concurrently.
whole blood and measures platelet ability to aggregate. The PFA-100 uses whole blood under high shear forces to assess platelet function and is more practical than aggregometry for the clinical setting. In humans, the collagen/epinephrine cartridge has been shown to be more likely to be influenced by medications, whereas the collagen/ADP cartridge is considered to be a more general indicator of platelet function. However, in dogs, there is some degree of test-to-test variability in closure times generated by the collagen/epinephrine cartridge, suggesting that this cartridge is not a precise indicator of drug-induced platelet dysfunction. To compensate for this variability, 2 samples per dog per time point were analyzed and averaged. The results of our platelet function analysis suggest that there is no detectable change in platelet function during treatment with cyclosporine. Our results were similar to those of a previous study that evaluated the effects of cyclosporine on canine platelet function, except that our study also utilized platelet aggregometry to provide an additional assessment of platelet function.

In hypercoagulable patients with hyperactive platelets may require a higher dose of aspirin to consistently inhibit platelet function. Even though our study demonstrated that cyclosporine-induced thromboxane synthesis did not enhance platelet aggregation and that the combination of cyclosporine with low-dose aspirin did not counteract the antiplatelet effects of aspirin, both the low-dose aspirin group and the combined low-dose aspirin and cyclosporine group had variable dog-to-dog inhibition of platelet function that is not seen with higher aspirin doses. Based on our aggregometry results on day 3, all of the dogs that were classified as responders with low-dose aspirin also were considered aspirin responders when low-dose aspirin was combined with cyclosporine. Similarly, on day 7, 4 of the 5 dogs that were considered aspirin responders during low-dose aspirin therapy also were responders when low-dose aspirin was combined with cyclosporine. The 1 dog that was classified as an aspirin responder when treated with low-dose aspirin, and classified as a nonresponder when cyclosporine was added to the aspirin therapy, had a decrease in the percentage aggregation at maximum amplitude of 23% when receiving combined low-dose aspirin and cyclosporine. In our study, to be considered an aspirin responder, the percentage aggregation at maximum amplitude must have decreased by 25% from the initial baseline. Therefore, this dog may be considered an aspirin responder with a few additional days of aspirin therapy, or a slightly increased aspirin dose. A higher dose of aspirin, but not as high as the anti-inflammatory dose used in this study, may provide a more consistent inhibition of platelet function, while still decreasing cyclosporine-induced thromboxane synthesis. The ideal antiplatelet dosage of aspirin which provides consistent inhibition of thromboxane synthesis and platelet function, while minimizing any adverse drug reactions, has not been determined in dogs.

Our study had several limitations. Firstly, this study was conducted in healthy dogs and not hypercoagulable or IMHA patients. It is possible that the thromboxane concentration in hypercoagulable patients treated with cyclosporine would be higher than that reported in this study, in which case a 1 mg/kg daily dosage of aspirin might be insufficient to adequately decrease thromboxane synthesis. Continued thromboxane synthesis, along with a decrease in the antiplatelet benefits of aspirin, still could predispose hypercoagulable patients to thromboembolism and necessitate higher doses of anti-coagulant and antiplatelet drugs. Secondly, despite a sample size calculation indicating that this study had appropriate power if 8 dogs were enrolled, a smaller number of dogs than expected completed the study. Unfortunately, 1 dog had to be removed from the study because of unexpected illness, which could explain why the study failed to detect a statistically significant decrease in thromboxane synthesis during low-dose aspirin administration.

Recently, cyclosporine has been shown to increase thromboxane synthesis in dogs, suggesting that the use of this medication could increase the risk of thromboembolism, especially in hypercoagulable patients. Our study indicates that, in normal dogs, low-dose aspirin is capable of inhibiting cyclosporine-induced thromboxane synthesis and that the concurrent use of these 2 medications does not significantly alter the antiplatelet effects of aspirin. Therefore, if cyclosporine is used in patients that may be at risk for thromboembolism, the concurrent use of low-dose aspirin may be advisable.

**Footnotes**

a Aspirin, Major Pharmaceuticals, Livonia, MI  
b Atopica, Novartis Animal Health, Greensboro, NC  
c 3.2% sodium citrate, Vacutainer tube, Becton Dickinson, Franklin Lakes, NJ  
d Chronolog 700 Whole Blood/Optical Lumi-Aggregometer, Chronolog Corporation, Haverton, PA  
e Chronolog 700 Manual; Chronolog Corporation  
f AGGRO/LINK 8; Chronolog Corporation  
g PFA-100®, Siemens Healthcare Diagnostics, Deerfield, IL  
h PFA Collagen/ADP Test Cartridge; Siemens Healthcare Diagnostics, Duluth, GA  
i PFA Collagen/EPI Test Cartridge; Siemens Healthcare Diagnostics  
j 11-dehydro-thromboxane B₂; EIA kit-Monoclonal, Cayman Chemical Co, Ann Arbor, MI  
k SpectraMax M5 Multi-Mode Microplate Reader, Molecular Devices, Sunnyvale, CA  
l ACE Alera Clinical Chemistry System, Alfa Wasserman, Inc., West Caldwell, NJ  
m SAS for Windows version 9.2, SAS Institute, Cary, NC, 2008

**Acknowledgments**

This study was funded by the Mississippi State University College of Veterinary Medicine Internal Competitive Research Grant and Dr. Hugh G. Ward Endowment.
Conflict of Interest Declaration: Authors declare no conflict of interest.

Off-label Antimicrobial Declaration: Authors declare no off-label use of antimicrobials.

References

1. Scott-Moncrieff JC, Treadwell NG, McCullough SM, Brooks MB. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001;37:220–227.

2. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 Cases (1988–1996). J Am Anim Hosp Assoc 1999;35:384–391.

3. Carr A, Panciera D, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 dogs. J Vet Intern Med 2002;16:504–509.

4. Weiss D, Brazzell J. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006;20:682–686.

5. Sobieszczyk P, Fishbein M, Goldhaber S. Acute pulmonary embolism: Don’t ignore the platelet. Circulation 2002;106 (14):1748–1749.

6. Cahan KD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004;36(Suppl 2S):378S–391S.

7. Grace A, Barradas M, Mikhailidis D, et al. Cyclosporine A enhances platelet aggregation. Kidney Int 1987;32:889–895.

8. Averna M, Barbagallo C, Ganci A, et al. Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney Int 2001;59:1574–1579.

9. Oskarsson HJ, Hofmeyer TG, Oliviari MT. Cyclosporine impairs the ability of human platelets to mediate vasodilatation. Hypertension 1997;29:1314–1321.

10. Thomason J, Lunsford K, Stokes J, et al. The effects of cyclosporine on platelet function and cyclooxygenase expression in normal dogs. J Vet Intern Med 2012;26:1389–1401.

11. Weinkle T, Center S, Randolph J, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases. J Am Vet Med Assoc 2005;226:1869–1880.

12. Ruan C, So S, Ruan K. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease. Life Sci 2011;88:24–30.

13. Patrono C, Dalen J, Fuster V, et al. Platelet-Active Drugs. In: Circulation. 2001;119:39s–63s.

14. Strombom J, Lunsford K, Mullins K, et al. Platelet cyclooxygenase expression in normal dogs. J Vet Intern Med 2012;25:1106–1112.

15. Archer T, Boothe D, Langston V, et al. Oral cyclosporine treatment in dogs: A review of the literature. J Vet Intern Med 2014;28:1–20.

16. Linnenmnn B, Schonberg J, Mani H, et al. Standardization of light transmittance aggregometry for monitoring anti-platelet therapy: An adjustment for platelet count is not necessary. J Thromb Haemost 2008;6:677–683.

17. van der Steh CTA, van Werkum JWM, Seeling TH, et al. To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment. Platelets 2007;18:550–553.

18. Mani H, Luxembourg B, Klafling C, et al. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005;58:747–750.

19. Cattaneo M, Lecchi A, Zighetti ML, et al. Platelet aggregation studies: Autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 2007;92:694–697.

20. Callan MB, Giger U. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res 2001;62:652–658.

21. Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, vonWillebrand’s Disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165:43–52.

22. Nielsen L, Zois N, Pedersen H, et al. Platelet function in dogs: Breed differences and effect of acetylsalicylic acid administration. Vet Clin Pathol 2007;36:267–273.

23. Morales F, Couto C, Iazbik M. Effects of 2 concentrations of sodium citrate on coagulation test results, von Willebrand Factor concentration, and platelet function in dogs. J Vet Intern Med 2007;21:472–475.

24. Hoh C, Smith S, McMichael M, et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. Am J Vet Res 2011;72:1038–1045.

25. Haines J, Thomason J, Bulla C, et al. In vitro and in vivo assessment of platelet function in healthy dogs during exposure to low-dose aspirin. Am J Vet Res 2016;77:174–185.

26. Adamo P, Rylander H, Adams W. Ciclosporin use in multi-drug therapy for meningoencephalomyelitis of unknown aetiology in dogs. J Small Anim Pract 2007;48:486–496.

27. Jespersen B, Thiesson H, Henriksen C, et al. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Nephrol Dial Transplant 2009;24:1644–1655.

28. Braun-Dullaeus R, Feussner M, Walker G, et al. Cyclosporine-induced coronary artery constriction-dissociation between thromboxane release and coronary vasospasm. J Heart Lung Transplant 1999;18:328–335.

29. Gonzalez-Correa J, De La Cruz J, Lucena M, et al. Effect of cyclosporine A on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thromb Res 1996;81:367–381.

30. Bultzer W, McMichael M, Ruaux C, et al. Measurement of urinary 11-dehydro-thromboxane B2 excretion in dogs with gastric dilatation-volvulus. Am J Vet Res 2006;67:78–83.

31. Mullins K, Thomason J, Lunsford K, et al. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. Vet Anaesth Analg 2012;39:206–217.

32. Johnson GJ, Leis LA, Rao GHR, White JG. Arachidonicate-induced platelet aggregation in the dog. Thromb Res 1979;14:147–154.

33. Johnson GJ, Leis LA, King RA. Thromboxane responsiveness of dog platelets in inherited as an autosomal recessive trait. Thromb Haemostasis 1991;65:578–580.

34. Johnson GJ, Leis LA, Dunlop PC. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction. J Clin Invest 1993;92:2469–2479.

35. Dudley A, Thomason J, Fritz S, et al. Cyclooxygenase Expression and Platelet Function in Normal Dogs Receiving Low Dose Aspirin. J Vet Intern Med 2013;27:141–149.

36. Rackear D, Feldman B, Farver T, et al. The effect of three different dosages of acetylsalicylic acid on canine platelet aggregation. J Am Anim Hosp Assoc 1988;24:23–26.

37. Lordkipanidze M, Pharand C, Schampaert E, et al. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry. Thromb Res 2009;124:418–422.

38. von Pape K, Aland E, Bohner J. Platelet function analysis with PFA-100® in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 2000;98:295–299.